Telix company updates including commercial manufacturing agreement

Click the links to view the following ASX announcements:

Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®

Telix Appoints Darren Patti, Chief Operating Officer, Telix Pharmaceuticals (US) Inc.

Telix Pharmaceuticals and ITM Complete Global Agreements for Lutetium-177 Radioisotope Supply

About Telix Pharmaceuticals Limited (ASX: TLX)

Telix is a late-stage radiopharmaceutical company developing a broad portfolio of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix’s products address significant unmet medical needs in prostate, kidney, glioblastoma (brain) and hematologic (blood) cancers, as well as a range of immunologic and high value rare diseases.

The Company is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States, and is listed on the Australian Securities Exchange (ASX: TLX).

Telix’s lead product, Illuccix® (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. Food and Drug Administration (FDA) and has been granted Priority Review status by the Australian Therapeutic Goods Administration (TGA). Telix is also progressing marketing authorisation applications for Illuccix® in the European Union and Canada. None of Telix’s products have currently received a marketing authorisation in any jurisdiction. For more information visit and follow Telix on Twitter (@TelixPharma) and LinkedIn.

Register Interest